{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T12:49:53Z","timestamp":1777207793651,"version":"3.51.4"},"reference-count":58,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_jtim-2026-0040_s_005\">\n                    <jats:title>Background and Objectives<\/jats:title>\n                    <jats:p>The chemotherapy response rate in head and neck squamous cell carcinoma (HNSCC) remains low due to a lack of effective therapeutic targets, and treatment efficacy is further limited by chemoresistance and heterogeneity in drug response. Sialylated cancer IgG (SIA-cIgG) is a tumor-derived immunoglobulin implicated in tumor stemness. However, the relationship between SIA-cIgG and chemoresistance, and its potential as a therapeutic target, remain to be determined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jtim-2026-0040_s_006\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We evaluated the antitumor eficacy of SIA-cIgG inhibition combined with four chemotherapeutic agents using two HNSCC cell lines with high or low SIA-cIgG expression, along with in vivo xenograft models. Furthermore, we investigated the functional roles of SIA-cIgG and its downstream effector PTPN13 in regulating HNSCC stemness. Patient-derived organoids (PDOs) from 25 HNSCC patients were used to compare the antitumor eficacy of anti-SIA-cIgG-based combinations against conventional clinical chemotherapy regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jtim-2026-0040_s_007\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Elevated SIA-cIgG protein levels correlated positively with an increased IC50 for cisplatin and poorer chemotherapy response. SIA-cIgG\/PTPN13 axis was critical for tumor stemness and chemoresistance. Anti-SIA-cIgG treatment enhanced PTPN13 protein stability and upregulated PTPN13 mRNA expression via SP1. Anti-SIA-cIgG-based drug combinations demonstrated significantly higher anticancer efficacy than conventional clinical chemotherapy regimens and overcame tumor heterogeneity in drug response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jtim-2026-0040_s_008\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>SIA-cIgG\/PTPN13 axis regulates tumor stemness and contributes to chemoresistance, anti-SIA-cIgG-based drug combinations exhibit significant potential for clinical application.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/jtim-2026-0040","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T12:58:47Z","timestamp":1774529927000},"page":"237-258","source":"Crossref","is-referenced-by-count":0,"title":["Anti-SIA-cIgG enhances chemotherapy effectiveness through PTPN13-regulated tumor stemness in head and neck squamous cell carcinoma"],"prefix":"10.1515","volume":"14","author":[{"given":"Luming","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology; National Center for Stomatology; National Clinical Research Center for Oral Diseases; National Engineering Research Center of Oral Biomaterials and Digital Medical Devices; Beijing Key Laboratory of Digital Stomatology; NHC Key Laboratory of Digital Stomatology; NMPA Key Laboratory for Dental Materials , Beijing , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangyang","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology; National Center for Stomatology; National Clinical Research Center for Oral Diseases; National Engineering Research Center of Oral Biomaterials and Digital Medical Devices; Beijing Key Laboratory of Digital Stomatology; NHC Key Laboratory of Digital Stomatology; NMPA Key Laboratory for Dental Materials , Beijing , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenshu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology; National Center for Stomatology; National Clinical Research Center for Oral Diseases; National Engineering Research Center of Oral Biomaterials and Digital Medical Devices; Beijing Key Laboratory of Digital Stomatology; NHC Key Laboratory of Digital Stomatology; NMPA Key Laboratory for Dental Materials , Beijing , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofeng","family":"Shan","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology; National Center for Stomatology; National Clinical Research Center for Oral Diseases; National Engineering Research Center of Oral Biomaterials and Digital Medical Devices; Beijing Key Laboratory of Digital Stomatology; NHC Key Laboratory of Digital Stomatology; NMPA Key Laboratory for Dental Materials , Beijing , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Sui","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology; National Center for Stomatology; National Clinical Research Center for Oral Diseases; National Engineering Research Center of Oral Biomaterials and Digital Medical Devices; Beijing Key Laboratory of Digital Stomatology; NHC Key Laboratory of Digital Stomatology; NMPA Key Laboratory for Dental Materials , Beijing , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1461-695X","authenticated-orcid":false,"given":"Shang","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology; National Center for Stomatology; National Clinical Research Center for Oral Diseases; National Engineering Research Center of Oral Biomaterials and Digital Medical Devices; Beijing Key Laboratory of Digital Stomatology; NHC Key Laboratory of Digital Stomatology; NMPA Key Laboratory for Dental Materials , Beijing , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7657-8843","authenticated-orcid":false,"given":"Zhigang","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology; National Center for Stomatology; National Clinical Research Center for Oral Diseases; National Engineering Research Center of Oral Biomaterials and Digital Medical Devices; Beijing Key Laboratory of Digital Stomatology; NHC Key Laboratory of Digital Stomatology; NMPA Key Laboratory for Dental Materials , Beijing , China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"2026042612202579296_j_jtim-2026-0040_ref_001","doi-asserted-by":"crossref","unstructured":"Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Primers 2020;6:92.","DOI":"10.1038\/s41572-020-00224-3"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_002","doi-asserted-by":"crossref","unstructured":"Machiels JP, Ren\u00e9 Leemans C, Golusinski W, Grau C, Licitra L, Gregoire V, et al. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020;31:1462-1475.","DOI":"10.1016\/j.annonc.2020.07.011"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_003","doi-asserted-by":"crossref","unstructured":"Pfister DG, Spencer S, Adelstein D, Adkins D, Anzai Y, Brizel DM, et al. Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2020;18:873-898.","DOI":"10.6004\/jnccn.2020.0031"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_004","doi-asserted-by":"crossref","unstructured":"Cramer JD, Burtness B, Le QT, Ferris RL. The changing therapeutic landscape of head and neck cancer. Nat Rev Clin Oncol 2019;16:669-683.","DOI":"10.1038\/s41571-019-0227-z"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_005","doi-asserted-by":"crossref","unstructured":"Ruffin AT, Li H, Vujanovic L, Zandberg DP, Ferris RL, Bruno TC. Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment. Nat Rev Cancer 2023;23:173-188.","DOI":"10.1038\/s41568-022-00531-9"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_006","doi-asserted-by":"crossref","unstructured":"Burtness B, Harrington KJ, Greil R, Souli\u00e8res D, Tahara M, de Castro G Jr, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 2019;394:1915-1928.","DOI":"10.1016\/S0140-6736(19)32591-7"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_007","doi-asserted-by":"crossref","unstructured":"Dzienis M, Cundom J, Fuentes CS, Spreafico A, Nordlinger M, Pastor AV, et al. Pembrolizumab plus carboplatin and paclitaxel as first-line therapy for recurrent\/metastatic head and neck squamous cell carcinoma (KEYNOTE-B10): A single-arm phase IV trial. J Clin Oncol 2024;42:2989-2999.","DOI":"10.1200\/JCO.23.02625"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_008","doi-asserted-by":"crossref","unstructured":"Guigay J, Aup\u00e9rin A, Fayette J, Saada-Bouzid E, Lafond C, Taberna M, et al. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 2021;22:463-475.","DOI":"10.2139\/ssrn.3700967"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_009","doi-asserted-by":"crossref","unstructured":"Guo Y, Luo Y, Zhang Q, Huang X, Li Z, Shen L, et al. First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and\/ or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomised, phase III CHANGE-2 trial. Eur J Cancer 2021;156:35-45.","DOI":"10.1016\/j.ejca.2021.06.039"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_010","doi-asserted-by":"crossref","unstructured":"Hughes BGM, Munoz-Couselo E, Mortier L, Bratland A, Gutzmer R, Roshdy O, et al. Pembrolizumab for locally advanced and recurrent\/ metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial. Ann Oncol 2021;32:1276-1285.","DOI":"10.1016\/j.annonc.2021.07.008"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_011","doi-asserted-by":"crossref","unstructured":"Osman AA, Arslan E, Bartels M, Michikawa C, Lindemann A, Tomczak K, et al. Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res 2023;29:1344-1359.","DOI":"10.1158\/1078-0432.CCR-22-2747"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_012","doi-asserted-by":"crossref","unstructured":"Yao Y, Wang Y, Chen L, Tian Z, Yang G, Wang R, et al. Clinical utility of PDX cohorts to reveal biomarkers of intrinsic resistance and clonal architecture changes underlying acquired resistance to cetuximab in HNSCC. Signal Transduct Target Ther 2022;7:73.","DOI":"10.1038\/s41392-022-00908-0"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_013","doi-asserted-by":"crossref","unstructured":"Cui M, Huang J, Zhang S, Liu Q, Liao Q, Qiu X. Immunoglobulin Expression in Cancer Cells and Its Critical Roles in Tumorigenesis. Front Immunol 2021;12:613530.","DOI":"10.3389\/fimmu.2021.613530"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_014","unstructured":"Qiu X, Zhu X, Zhang L, Mao Y, Zhang J, Hao P, et al. Human epithelial cancers secrete immunoglobulin g with unidentified specificity to promote growth and survival of tumor cells. Cancer Res 2003;63:6488-6495."},{"key":"2026042612202579296_j_jtim-2026-0040_ref_015","doi-asserted-by":"crossref","unstructured":"Wang Z, Geng Z, Shao W, Liu E, Zhang J, Tang J, et al. Cancer-derived sialylated IgG promotes tumor immune escape by binding to Siglecs on effector T cells. Cell Mol Immunol 2020; 17: 1148-1162.","DOI":"10.1038\/s41423-019-0327-9"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_016","doi-asserted-by":"crossref","unstructured":"Xu M, Zhang S, Zhang Y, Qiu X, Wang X. High Expression of Cancer-Derived Sialylated Immunoglobulin G: A Novel Biomarker for Poor Prognosis in Laryngeal Squamous Cell Carcinoma. Oncology 2025;103:227-236.","DOI":"10.1159\/000540465"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_017","doi-asserted-by":"crossref","unstructured":"Tang J, Zhang J, Liu Y, Liao Q, Huang J, Geng Z, et al. Lung squamous cell carcinoma cells express non-canonically glycosylated IgG that activates integrin-FAK signaling. Cancer Lett 2018;430:148-159.","DOI":"10.1016\/j.canlet.2018.05.024"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_018","doi-asserted-by":"crossref","unstructured":"Yang B, Ma C, Chen Z, Yi W, McNutt MA, Wang Y, et al. Correlation of immunoglobulin G expression and histological subtype and stage in breast cancer. PLoS One 2013;8:e58706.","DOI":"10.1371\/journal.pone.0058706"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_019","doi-asserted-by":"crossref","unstructured":"Ma C, Wang Y, Zhang G, Chen Z, Qiu Y, Li J, et al. Immunoglobulin G expression and its potential role in primary and metastatic breast cancers. Curr Mol Med 2013;13:429-437.","DOI":"10.2174\/1566524011313030012"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_020","doi-asserted-by":"crossref","unstructured":"Niu N, Zhang J, Huang T, Sun Y, Chen Z, Yi W, et al. IgG expression in human colorectal cancer and its relationship to cancer cell behaviors. PLoS One 2012;7:e47362.","DOI":"10.1371\/journal.pone.0047362"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_021","doi-asserted-by":"crossref","unstructured":"Cui M, You L, Zheng B, Huang X, Liu Q, Huang J, et al. High expression of cancer-derived glycosylated immunoglobulin G predicts poor prognosis in pancreatic ductal adenocarcinoma. J Cancer 2020;11:2213-2221.","DOI":"10.7150\/jca.39800"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_022","doi-asserted-by":"crossref","unstructured":"Qin C, Sheng Z, Huang X, Tang J, Liu Y, Xu T, et al. Cancer-driven IgG promotes the development of prostate cancer though the SOX2-CIgG pathway. Prostate 2020;80:1134-1144.","DOI":"10.1002\/pros.24042"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_023","doi-asserted-by":"crossref","unstructured":"Zhu X, Li C, Sun X, Mao Y, Li G, Liu X, et al. Immunoglobulin mRNA and protein expression in human oral epithelial tumor cells. Appl Immunohistochem Mol Morphol 2008;16:232-238.","DOI":"10.1097\/PAI.0b013e31814c915a"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_024","doi-asserted-by":"crossref","unstructured":"Yang X, Wang G, You J, Gu R, Xu X, Xu C, et al. High Expression of Cancer-IgG Is Associated With Poor Prognosis and Radioresistance via PI3K\/AKT\/DNA-PKcs Pathway Regulation in Lung Adenocarcinoma. Front Oncol 2021;11:675397.","DOI":"10.3389\/fonc.2021.675397"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_025","doi-asserted-by":"crossref","unstructured":"Cui M, Shoucair S, Liao Q, Qiu X, Kinny-K\u00f6ster B, Habib JR, et al. Cancer-cell-derived sialylated IgG as a novel biomarker for predicting poor pathological response to neoadjuvant therapy and prognosis in pancreatic cancer. Int J Surg 2023;109:99-106.","DOI":"10.1097\/JS9.0000000000000200"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_026","doi-asserted-by":"crossref","unstructured":"Huang X, Zhang S, Tang J, Tian T, Pan Y, Wu L, et al. A self-propagating c-Met-SOX2 axis drives cancer-derived IgG signaling that promotes lung cancer cell stemness. Cancer Res 2023;83:1866-1882.","DOI":"10.1158\/0008-5472.CAN-22-2733"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_027","doi-asserted-by":"crossref","unstructured":"Prasetyanti PR, Medema JP. Intra-tumor heterogeneity from a cancer stem cell perspective. Mol Cancer 2017;16:41.","DOI":"10.1186\/s12943-017-0600-4"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_028","doi-asserted-by":"crossref","unstructured":"Yang L, Shi P, Zhao G, Xu J, Peng W, Zhang J, et al. Targeting cancer stem cell pathways for cancer therapy. Signal Transduct Target Ther 2020;5:8.","DOI":"10.1038\/s41392-020-0110-5"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_029","doi-asserted-by":"crossref","unstructured":"Wang LM, Gan YH. Cancer-derived IgG involved in cisplatin resistance through PTP-BAS\/Src\/PDK1\/AKT signaling pathway. Oral Dis 2021;27:464-474.","DOI":"10.1111\/odi.13583"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_030","doi-asserted-by":"crossref","unstructured":"Yan Y, Huang P, Mao K, He C, Xu Q, Zhang M, et al. Anti-oncogene PTPN13 inactivation by hepatitis B virus X protein counteracts IGF 2BP1 to promote hepatocellular carcinoma progression. Oncogene 2021;40:28-45.","DOI":"10.1038\/s41388-020-01498-3"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_031","doi-asserted-by":"crossref","unstructured":"Glondu-Lassis M, Dromard M, Lacroix-Triki M, Nird\u00e9 P, Puech C, Knani D, et al. PTPL1\/PTPN13 regulates breast cancer cell aggressiveness through direct inactivation of Src kinase. Cancer Res 2010;70:5116-5126.","DOI":"10.1158\/0008-5472.CAN-09-4368"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_032","doi-asserted-by":"crossref","unstructured":"Aptecar L, Puech C, Lopez-Crapez E, Peter M, Coopman P, D\u2019Hondt V, et al. PTPN 13 Participates in the Regulation of Epithelial-Mesenchymal Transition and Platinum Sensitivity in High-Grade Serous Ovarian Carcinoma Cells. Int J Mol Sci 2023;24:15413.","DOI":"10.3390\/ijms242015413"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_033","doi-asserted-by":"crossref","unstructured":"Zhang XY, Sui Y, Shan XF, Wang LM, Zhang L, Xie S, et al. Construction of oral squamous cell carcinoma organoids in vitro 3D-culture for drug screening. Oral Dis 2025;31:99-109.","DOI":"10.1111\/odi.15044"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_034","doi-asserted-by":"crossref","unstructured":"Driehuis E, Kolders S, Spelier S, L\u00f5hmussaar K, Willems SM, Devriese LA, et al. Oral Mucosal Organoids as a Potential Platform for Personalized Cancer Therapy. Cancer Discov 2019;9:852-871.","DOI":"10.1158\/2159-8290.CD-18-1522"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_035","doi-asserted-by":"crossref","unstructured":"Veninga V, Voest EE. Tumor organoids: Opportunities and challenges to guide precision medicine. Cancer Cell 2021;39:1190-1201.","DOI":"10.1016\/j.ccell.2021.07.020"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_036","doi-asserted-by":"crossref","unstructured":"Siqueira JM, Heguedusch D, Rodini CO, Nunes FD, Rodrigues MFSD. Mechanisms involved in cancer stem cell resistance in head and neck squamous cell carcinoma. Cancer Drug Resist 2023;6:116-137.","DOI":"10.20517\/cdr.2022.107"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_037","doi-asserted-by":"crossref","unstructured":"Liu R, Chen Y, Liu G, Li C, Song Y, Cao Z, et al. PI3K\/AKT pathway as a key link modulates the multidrug resistance of cancers. Cell Death Dis 2020;11:797.","DOI":"10.1038\/s41419-020-02998-6"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_038","doi-asserted-by":"crossref","unstructured":"Hu Y, Smyth GK. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods 2009;347:70-78.","DOI":"10.1016\/j.jim.2009.06.008"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_039","doi-asserted-by":"crossref","unstructured":"Hashemi M, Arani HZ, Orouei S, Fallah S, Ghorbani A, Khaledabadi M, et al. Biomed Pharmacother 2022;155:113774.","DOI":"10.1016\/j.biopha.2022.113774"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_040","doi-asserted-by":"crossref","unstructured":"Usman S, Waseem NH, Nguyen TKN, Mohsin S, Jamal A, Teh MT, et al. Vimentin Is at the Heart of Epithelial Mesenchymal Transition (EMT) Mediated Metastasis. Cancers (Basel) 2021;13:4985.","DOI":"10.3390\/cancers13194985"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_041","doi-asserted-by":"crossref","unstructured":"Yin S, Yu Y, Wu N, Zhuo M, Wang Y, Niu Y, et al. Patient-derived tumor-like cell clusters for personalized chemo- and immunotherapies in non-small cell lung cancer. Cell Stem Cell 2024;31:717-733.e8.","DOI":"10.1016\/j.stem.2024.03.008"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_042","doi-asserted-by":"crossref","unstructured":"Bhatia A, Burtness B. Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update. Drugs 2023;83:217-248.","DOI":"10.1007\/s40265-023-01835-2"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_043","doi-asserted-by":"crossref","unstructured":"He Y, Sun MM, Zhang GG, Yang J, Chen KS, Xu WW, et al. Targeting PI3K\/Akt signal transduction for cancer therapy. Signal Transduct Target Ther 2021;6:425.","DOI":"10.1038\/s41392-021-00828-5"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_044","doi-asserted-by":"crossref","unstructured":"Hoxhaj G, Manning BD. The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. Nat Rev Cancer 2020;20:74-88.","DOI":"10.1038\/s41568-019-0216-7"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_045","doi-asserted-by":"crossref","unstructured":"Kajiwara K, Chen PK, Abe Y, Okuda S, Kon S, Adachi J, et al. Src activation in lipid rafts confers epithelial cells with invasive potential to escape from apical extrusion during cell competition. Curr Biol 2022;32:3460-3476. e6.","DOI":"10.1016\/j.cub.2022.06.038"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_046","doi-asserted-by":"crossref","unstructured":"Xu R, Song J, Ruze R, Chen Y, Yin X, Wang C, et al. SQLE promotes pancreatic cancer growth by attenuating ER stress and activating lipid rafts-regulated Src\/PI3K\/Akt signaling pathway. Cell Death Dis 2023;14:497.","DOI":"10.1038\/s41419-023-05987-7"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_047","doi-asserted-by":"crossref","unstructured":"Lin Y, Yang Y, Li W, Chen Q, Li J, Pan X, et al. Reciprocal regulation of Akt and Oct4 promotes the self-renewal and survival of embryonal carcinoma cells. Mol Cell 2012;48:627-640.","DOI":"10.1016\/j.molcel.2012.08.030"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_048","doi-asserted-by":"crossref","unstructured":"Schaefer T, Lengerke C. SOX2 protein biochemistry in stemness, reprogramming, and cancer: the PI3K\/AKT\/SOX2 axis and beyond. Oncogene 2020;39:278-292.","DOI":"10.1038\/s41388-019-0997-x"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_049","doi-asserted-by":"crossref","unstructured":"Beishline K, Azizkhan-Clifford J. Sp1 and the \u2018hallmarks of cancer\u2019. FEBS J 2015;282:224-258.","DOI":"10.1111\/febs.13148"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_050","doi-asserted-by":"crossref","unstructured":"Wang X, Pan L, Feng Y, Wang Y, Han Q, Han L, et al. P300 plays a role in p16(INK4a) expression and cell cycle arrest. Oncogene 2008;27:1894-1904.","DOI":"10.1038\/sj.onc.1210821"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_051","doi-asserted-by":"crossref","unstructured":"Chen J, Zhang S, Huang X, Wang Q, Xu W, Huang J, et al. Sialylated IgG-activated integrin \u03b24-Src-Erk axis stabilizes c-Myc in a p300 lysine acetyltransferase-dependent manner to promote colorectal cancer liver metastasis. Neoplasia 2025;61:101140.","DOI":"10.1016\/j.neo.2025.101140"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_052","doi-asserted-by":"crossref","unstructured":"Xu W, Zhu Q, Wu Z, Guo H, Wu F, Mashausi DS, et al. A novel evolutionarily conserved element is a general transcriptional repressor of p21WAF1\/CIP1. Cancer Res 2012;72:6236-6246.","DOI":"10.1158\/0008-5472.CAN-12-1236"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_053","doi-asserted-by":"crossref","unstructured":"Li F, Zheng Z, Chen W, Li D, Zhang H, Zhu Y, Mo Q, Zhao X, Fan Q, Deng F, Han C, Tan W. Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms. Drug Resist Updat 2023;68:100938.","DOI":"10.1016\/j.drup.2023.100938"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_054","doi-asserted-by":"crossref","unstructured":"Tapias A, Ciudad CJ, Roninson IB, No\u00e9 V. Regulation of Sp1 by cell cycle related proteins. Cell Cycle 2008;7:2856-2867.","DOI":"10.4161\/cc.7.18.6671"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_055","doi-asserted-by":"crossref","unstructured":"Li Q, Yang G, Feng M, Zheng S, Cao Z, Qiu J, et al. NF-\u03baB in pancreatic cancer: Its key role in chemoresistance. Cancer Lett 2018;421:127-134.","DOI":"10.1016\/j.canlet.2018.02.011"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_056","doi-asserted-by":"crossref","unstructured":"Liang Y, Wang Y, Zhang Y, Ye F, Luo D, Li Y, et al. HSPB1 facilitates chemoresistance through inhibiting ferroptotic cancer cell death and regulating NF-\u03baB signaling pathway in breast cancer. Cell Death Dis 2023;14:434.","DOI":"10.1038\/s41419-023-05972-0"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_057","doi-asserted-by":"crossref","unstructured":"Yu H, Lin L, Zhang Z, Zhang H, Hu H. Targeting NF-\u03baB pathway for the therapy of diseases: mechanism and clinical study. Signal Transduct Target Ther 2020;5:209.","DOI":"10.1038\/s41392-020-00312-6"},{"key":"2026042612202579296_j_jtim-2026-0040_ref_058","doi-asserted-by":"crossref","unstructured":"Xie Q, Hua X, Huang C, Liao X, Tian Z, Xu J, et al. SOX2 Promotes Invasion in Human Bladder Cancers through MMP2 Upregulation and FOXO1 Downregulation. Int J Mol Sci 2022;23:12532.","DOI":"10.3390\/ijms232012532"}],"container-title":["Journal of Translational Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jtim-2026-0040\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jtim-2026-0040\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T12:23:44Z","timestamp":1777206224000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jtim-2026-0040\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":58,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,12,5]]},"published-print":{"date-parts":[[2026,4,21]]}},"alternative-id":["10.1515\/jtim-2026-0040"],"URL":"https:\/\/doi.org\/10.1515\/jtim-2026-0040","relation":{},"ISSN":["2224-4018"],"issn-type":[{"value":"2224-4018","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]}}}